Challenges for Clinical Cannabis and Cannabinoid Research in the United States
Ziva D. Cooper(Neurobehavioral Systems), Douglas C. Throckmorton(United States Food and Drug Administration), Steven W. Gust(National Institutes of Health), Alejandro Salicrup(National Institutes of Health), Donald I. Abrams(California Institute of Integral Studies)
Cited by 107
Related Papers
Cannabis in painful HIV-associated sensory neuropathy
|Neurology|2007|595
Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling
|Clinical Pharmacology & Therapeutics|2007|582
High-Level Expression of a Recombinant Antibody from Myeloma Cells Using a Glutamine Synthetase Gene as an Amplifiable Selectable Marker
|Nature Biotechnology|1992|465
Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium
|Nature Biotechnology|2010|406